ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Association between induced organ atrophy assessed by artificial intelligence-generated automatic segmentation and efficacy of bevacizumab in combination with chemotherapy in metastatic colorectal cancer.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBevacizumab, an angiogenesis inhibitor, is commonly used alongside chemotherapy for metastatic colorectal cancer (mCCR). While inducing necrosis in tumours, bevacizumab may also lead to atrophy in tumour-free organs. Artificial intelligence (AI) models offer user-friendly methods for measuring organ volumes. This study explores the relationship between bevacizumab-induced atrophy using AI-assisted volume measurement in tumour-free organs and treatment efficacy.
methodsThis multicenter retrospective study includes patients from the PRODIGE 9 and PRODIGE 20 trials. Organ atrophy was assessed by evaluating volume changes from diagnosis to two months after treatment initiation in patients receiving bevacizumab compared to those who did not. Statistical analyses were performed using the Wilcoxon test, with correlations between volumetric changes. Overall and progression-free survival were assessed using log-rank tests and Cox regression models.
resultsAmong the 214 patients included, 192 received bevacizumab. Both liver and spleen volumes were measured using a deep learning-based AI model and manual measurements. AI-generated volume measurements showed a strong correlation with manual measurements (Pearson coefficient > 0.8). Bevacizumab-treated patients exhibited significant atrophy of non-tumoural liver volume (p = 0.0378), while no significant changes were observed in tumour or spleen volumes in either group. Survival analyses revealed that patients with a smaller decrease in non-tumoural liver volume had improved overall survival (p = 0.016), although this association became non-significant after adjusting for age, sex, and tumour volume at diagnosis (p = 0.25).
conclusionOur findings support the feasibility and reliability of AI in organ volume measurement. While bevacizumab exposure was linked to non-tumoural liver atrophy, its impact on survival remains inconclusive after adjustment. These results pave the way for further research into bevacizumab-induced organ atrophy and the potential of AI in personalizing oncology treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.